AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen(R) as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver
In: GlobeNewswire, 2022-04-11
Zeitungsartikel
Zugriff:
OCALA, Apr 11, 2022 (GLOBE NEWSWIRE via COMTEX) -- Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046) Data suggest that CKM regimen with Ampligen [...]
Titel: |
AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen(R) as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver
|
---|---|
Zeitschrift: | GlobeNewswire, 2022-04-11 |
Veröffentlichung: | 2022 |
Medientyp: | Zeitungsartikel |
Schlagwort: |
|
Sonstiges: |
|